Researchers have designed a potential new treatment for one of the most common forms of muscular dystrophy, according to a new study published today in the Proceedings of the National Academy of Sciences. Toshifumi Yokota, professor of medical genetics at the University of Alberta, led a team from Canada and the U.S. to create and test synthetic DNA-like molecules that interfere with the production of a toxic protein that destroys the muscles of people who have facioscapulohumeral muscular dystrophy (FSHD).
- Airflow modeling suggests driving with all windows down safest to prevent COVID-19 transmission
- Lung tissue from COVID-19 patients and others reveals promising target to treat lung fibrosis
- Riding in a car in the pandemic: which windows to open?
- The heavier, the better — superior stability in isotope functionalized perovskites
- Hidden structure found in essential metabolic machinery